We are investigating Andexxa blood clot side effects cases for patients who developed a pulmonary embolism or deep vein thrombosis causing them to be hospitalized or resulting in their death.
Here are some basic facts about these Andexxa drug injury cases seeking legal compensation:
- Andexxa (andexanet) is a treatment used when the reversal of anticoagulation is needed for life-threatening or uncontrolled bleeding in patients who are using Eliquis (apixaban) or Xarelto (rivaroxaban).
- For Andexxa drug injury cases to be successful, the patients must be using this anticoagulant reversal drug at the time of their pulmonary embolism (PE) or deep vein thrombosis (DVT) diagnosis.
- The FDA has been looking into an apparent increased rate of Andexxa blood clot side effects, that can lead to DVT and/or PE as well as clotting-related deaths, compared with a different means to reverse anticoagulation.
- Because there are no warnings in the current Andexxa drug label about an increased risk of blood clot side effects for patients using Andexxa, these drug injury lawsuits would not be filed against patients’ doctors.
- These cases would be filed as Andexxa drug injury lawsuits against AstraZeneca, the responsible pharmaceutical company.
We will continue to monitor this relatively new drug safety issue of Andexxa blood clot side effects causing pulmonary embolism (PE) or deep vein thrombosis (DVT).
Free Case Evaluation for Andexxa Blood Clot Side Effects
We encourage you to submit a Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Andexxa drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – based on his over 25 years of experience handling drug injury cases.
Most Recent Article About Andexxa Causing Blood Clots, PE, DVT
Andexxa Blood Clot Cases Before Any AstraZeneca Drug Recall
Following a November 2024 FDA Advisory Committee meeting, drug injury lawsuits against AstraZeneca concerning Andexxa blood clot cases for patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT) are likely to be filed.
Of course, these Andexxa blood clot cases would have to occur before any AstraZeneca drug recall for Andexxa because the patients would have to be using this anticoagulant reversal drug at the time of their PE or DVT diagnosis for the Andexxa drug injury lawsuits to be successful.
At this time, it is unclear whether there will be an AstraZeneca drug recall of Andexxa. Some possibilities are that the FDA will seek withdrawal of this AstraZeneca anticoagulant reversal drug or request additional confirmatory data for Andexxa, as seen below.
To read more of this article, click below:
From a December 17, 2024, FirstWord PHARMA news report, “Fate of AstraZeneca’s Andexxa unclear as FDA rejects full approval”:
Less than a month after a bruising FDA advisory committee meeting, the agency has issued a complete response letter (CRL) regarding AstraZeneca’s bid to convert its anticoagulant reversal drug Andexxa (andexanet alfa) from accelerated to full approval.
The fate of Andexxa is unclear at this stage; the FDA could seek withdrawal of the drug or ask for additional confirmatory data. AstraZeneca told FirstWord that “while discussions with the FDA are ongoing, Andexxa will remain on the US market.”
And from a December 13, 2024, Pink Sheet news report, “AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response”:
The next steps for the drug following the [FDA-issued complete response letter [(CRL)], which has not been publicly announced by the company, are unclear. Neither AstraZeneca nor FDA would provide much additional information about the product’s standing….
The agency could move to withdraw the drug from the market or ask the company to conduct additional studies to verify a favorable risk-benefit balance.
AstraZeneca told the Pink Sheet that the drug will remain on the US market while discussions with the agency about next steps continue. But the company would not comment on whether those discussions include potential new trials.
We are interested in hearing from patients who developed a pulmonary embolism (PE) or deep vein thrombosis (DVT) to investigate those situations as possible Andexxa blood clot cases that would be filed as drug injury lawsuits against AstraZeneca.
[Read the article in full at source]Earlier articles about Andexxa blood clot side effects: